氰肽氟苯胺對人類肝癌細胞株之影響與相關機制之探討

氰肽氟苯胺是一種口服選擇性血清素再攝取抑制劑製劑，為臨床上常用的抗精神病用藥，對治療重度憂鬱症有很好的療效。臨床上統計，服用抗精神病藥物之患者，其罹患癌症之機率相較於一般人為低，但原因並不清楚，故本論文擬探討抗精神病藥物是否可以降低癌症的發生。在本論文選用肝癌細胞株 HepG2 偵測氰肽氟苯胺抑制癌症的能力。細胞存活率試驗初步結果顯示氰肽氟苯胺可以以time-dependent及dosage- dependent的方式抑制肝癌細胞株 HepG2 的生長。此外，目前的實驗結果亦證實氰肽氟苯胺可以用dosage-dependent的方式引發肝癌細胞株 HepG2 的細胞自噬作用。綜合上述的結果，可知氰肽氟苯胺可以誘發肝癌細胞株產生自噬作用，但詳細的之分子機制，則有待未來更進一步研究的釐清。

Escitalopram oxalate is an oral selective serotonin reuptake inhibitors (SSRIs) preparation. It is a commonly used antipsychotic agent in clinical practice and is used to treat major depressive disorder (MDD). Has a good effect. According to clinical statistics, patients taking antipsychotics have a lower risk of cancer than the average person, but the reason is not clear. Therefore, this paper intends to investigate whether antipsychotic drugs can reduce the incidence of cancer. In this thesis, the liver cancer cell line HepG2 was used to detect the ability of escitalopram oxalate to inhibit cancer. Preliminary results showed that escitalopram oxalate inhibited the growth of hepatoma cell line HepG2 in a time-dependent and dose-dependent manner by MTT assay. In addition, the current experimental results also confirmed that escitalopram oxalate can induce autophagy of liver cancer cell line HepG2 in dose-dependent manner. Based on the above results, it can be seen that cyanopeptide fluoroaniline can induce autophagy in liver cancer cell lines, but the detailed molecular mechanism needs further clarification in the future.